GlaxoSmithKline has announced a $350 million deal with U.K. biotech company Adaptimmune which could be a "real shift" in the way cancer is treated, CNBC's Catherine Boyle reports.
ENJOY GREECE
We Explore, Find, Check & Propose You for the Truth - Enjoy GREECE - Enjoy EUROPE - Enjoy WORLD
